✦ LIBER ✦

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

✍ Scribed by Mamolo, C.; Harness, J.; Tan, H.; Menter, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patient-reported outcomes in moderate-to

✍ S. Tyring; J. Bagel; C. Lynde; P. Klekotka; E.H.Z. Thompson; S.R. Gandra; Y. Shi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

Improvements in patient-reported outcome

✍ Vibeke Strand, David Fiorentino, ChiaChi Hu… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 457 KB

A 2-week multiple ascending dose, double

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 49 KB

P300 Health related quality of life resu

✍ B. Feagan; C. Gasink; L.-L. Gao; M. Blank; J. Johanns; C. Guzzo; C.-F. Chiou; W. 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 67 KB

A Multicenter, Randomized, Double-Blind,

✍ William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Joha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 145 KB